Lebwohl, Mark (2020), "Supplement for "Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)""

Name: Lebwohl, Mark (2020), "Supplement for "Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)""
Creator: Mark Lebwohl
Published: 2020-09-18T11:04:13.900Z
Keywords: Dermatology

Lebwohl, Mark; Kircik , Leon; Lacour , Jean-Philippe; Liljedahl , Monika; Lynde , Charles; Moerch  , Marie Holst; Papp , Kim A.; Perrot , Jean-Luc; Stein Gold, Linda; Takhar , Amrit; Thaçi , Diamant; Warren , Richard B.; Wollenberg , Andreas

doi:10.17632/27h89s5wpx.5

Lebwohl, Mark (2020), "Supplement for "Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)""

Published: 18 September 2020| Version 5 | DOI: 10.17632/27h89s5wpx.5

Contributors:

Mark Lebwohl, Leon Kircik , Jean-Philippe Lacour , Monika Liljedahl , Charles Lynde , Marie Holst Moerch , Kim A. Papp , Jean-Luc Perrot , Linda Stein Gold, Amrit Takhar , Diamant Thaçi , Richard B. Warren , Andreas Wollenberg

Description

Supplementary material A presents the trial design and interventions of the PSO-LONG trial. Supplementary material B provides an overview of adverse events adjudicated as related to long-term corticosteroid use. Supplementary material C details the list of Principal Investigators who supported with the study.

Lebwohl, Mark (2020), "Supplement for "Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)""

Description

Files

Categories

Licence